ARCHIVES

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

Guest Editorial: Even Slam-Dunk Applications Can Benefit From Public Scrutiny and Discussion at ODAC

August 10, 2012

Greenberg: More Work Needs to be Done

November 7, 2014

NCI Launches NCORP with 53 Grants Totaling $465 Million

August 8, 2014

M.D. Anderson Closes Trials following FDA Requests for Data

February 16, 1996

NCI Begins Ovarian Cancer Trial To Build Blood Samples

October 28, 2005

PET/CT Imaging During Treatment Shows Whether Chemo Is Working, Study Finds

April 24, 2009